If needed to achieve glycemic goals, use of anti-diabetic agents showing potential CV benefits (e.g., metformin, pioglitazone) or proven CV safety (e.g., DPP-4 inhibitors, lixisenatide, exenatide, insulin, glimepiride) with lower risks of hypoglycemia is recommended [49]. This evidence concerns the gene DPP4 and Hypoglycemia.